[An alarming health check-up: what a bloody plasma!] / Un bilan alarmant : un plasma sanglant !

A 35-year-old patient with a metabolic pathology was hospitalized for programmed fibroscopy under general anesthesia for investigation and management of portal hypertension. Following the operation, he showed signs of sepsis and was transferred to intensive care unit. Biological analyzes carried out and generated automaton alarms for certain parameters. A visual check of the appearance of the sample revealed an unusual color of plasma. Additional informations obtained from the clinical department did not provide any explanation for this coloration. Additional assays confirmed an overdose of vitamin B12 related to the treatment of his pathology and which is responsible for the interference observed. Hence the interest of checking the reaction curves in the event of suspected interference and, if necessary, of making dilutions in order to reduce the effects on the biological assays.

Targeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stress.

Tacrolimus (FK506) is an immunosuppressant that is experiencing a continuous rise in usage worldwide. The related side effects are known to be globally dose-dependent. Despite numerous studies on FK506, the mechanisms underlying FK506 toxicity are still not well understood. It is therefore essential to explore the toxicity mediated by FK506. To accomplish this, we conducted a targeted metabolomic analysis using LC-MS on the plasma samples of patients undergoing FK506 treatment. The aim was to identify any associated altered metabolic pathway. Another anti-calcineurin immunosuppressive therapy, ciclosporin (CSA), was also studied. Increased plasma concentrations of pipecolic acid (PA) and sarcosine, along with a decrease in the glycine/sarcosine ratio and a tendency of increased plasma lysine was observed in patients under FK506 compared to control samples. Patients under CSA do not show an increase in plasma PA compared to the control samples, which does not support a metabolic link between the calcineurin and PA. The metabolomics changes observed in patients under FK506 highlight a possible link between FK506 and the action of an enzyme involved in both PA and sarcosine catabolism and oxidative pathway, the Peroxisomal sarcosine oxidase (PIPOX). Moreover, PA could be investigated as a potential biomarker of early nephrotoxicity in the follow-up of patients under FK506.